References
- King WJ, Greene GL. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature 1984; 307: 745–7
- Regan MM, Gelber RD. Predicting response to systemic treatments: Learning from the past to plan for the future. Breast 2005; 14: 582–93
- Andea AA, Bouwman D, Wallis T, Visscher DW. Correlation of tumor volume and surface area with lymph node status in patients with multifocal/multicentric breast carcinoma. Cancer 2004; 100: 20–7
- Coombs NJ, Boyages J. Multifocal and multicentric breast cancer: Does each focus matter?. J Clin Oncol 2005; 23: 7497–502
- Poulsen HS, Jensen J, Hermansen C. Human breast cancer: Heterogeneity of estrogen binding sites. Cancer 1981; 48: 1791–3
- Panahy C, Puddefoot JR, Anderson E, Vinson GP, Berry CL, Turner MJ, et al. Oestrogen and progesterone receptor distribution in the cancerous breast. Br J Cancer 1987; 55: 459–62
- Cawkwell L, Gray S, Murgatroyd H, Sutherland F, Haine L, Longfellow M, et al. Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut 1999; 45: 409–15
- Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474–81
- Coradini D, Oriana S, Mariani L, Miceli R, Bresciani G, Marubini E, et al. Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour?. Eur J Cancer 1998; 34: 825–30
- Tse GM, Kung FY, Chan AB, Law BK, Chang AR, Lo KW. Clonal analysis of bilateral mammary carcinomas by clinical evaluation and partial allelotyping. Am J Clin Pathol 2003; 120: 168–74
- Smeds J, Warngerg F, Norberg T, Nordgren H, Holmberg L, Bergh J. Ductal carcinoma in situ of the breast with different histopathological grades and corresponding new breast tumour events: Analysis of loss of heterozygosity. Acta Oncol 2005; 44: 41–9